Compass Pathways announces the first-ever study of psilocybin therapy on autistic adults, using COMP360.
With just a month left before the end of New York’s legislative session, lawmakers sponsoring differing psychedelics reform legislation recently participated in a discussion on the path forward for psilocybin in the Empire State.
Mydecine announces raising $1,693,434.60 in addition to gross proceeds of $333,333.35 announced on March 22, 2022.
Optimi Health announces the opening of Canada's largest GMP-grade psilocybin cultivation operating, including a 10,000 square foot production facility.
Incannex Healthcare announces a "shareholder loyalty option" to raise A$23.6 million (US$16.5 million). For every two shares purchased, investors will receive a "piggyback option".
Tryp Therapeutics announces initial patient enrollment in its Phase II clinical trial of a psilocybin-based compound (TRP-8802) for Binge Eating Disorder.
Field Trip announces its corporate decision to separate Field Trip Health and Field Trip Discovery into separate companies.